Clinical and Histopathologic Characteristics of Patient Population
| Initial diagnosis | Treatment course before B/I therapy | Before B/I therapy | PFS/OS analysis | |||||||||||
| Patient no. | Sex | Age at initial diagnosis (y) | Tumor location | Tumor type | KPS* | No. of recurrences during treatment course | Surgery | Radiation† (Gy) | Chemotherapy | Tumor type | KPS* | PFS | OS | rOS |
| 1 | F | 53 | R/T | GBM IV | 90 | 2 | (0)MTR (1, 2)MTR | (0)60 | (0)TMZ (1)TMZ | GBM IV | 70 | 4.8 | 81.9 | 5.4 |
| 2 | M | 37 | R/T | GBM IV | 90 | 3 | (0)MTR (1, 3)MTR | (0)60 | (0)TMZ (1)SUT, (2)TMZ | GBM IV | 60 | 2.7 | 45.7 | 3.6 |
| 3 | M | 60 | L/P | GBM IV | 100 | 2 | (0)MTR | (0)60 | (0)TMZ (1)TMZ | GBM IV | 70 | 5.4 | Alive | Alive |
| 4 | M | 63 | L/P | GBM IV | 80 | 2 | (0)PR | (0)60 | (0)TMZ (1)SUT | GBM IV | 80 | 1.8 | 18.2 | 6.5 |
| 5 | F | 69 | R/T | GS IV | 90 | 2 | (0)MTR | (0)60 | (0)TMZ (1)SUT | GS IV | 50 | 4.3 | 23.3 | 5.9 |
| 6 | F | 46 | L/F | ODG III–IV | 90 | 3 | (0)PR(1, 2)MTR | (0)− (1, 2)60 | (0)PCV (1)TMZ | sGBM IV HISTO | 80 | 9.9 | 50.4 | 10.9 |
| 7 | M | 37 | R/F-T | AA III | 100 | 2 | (0)MTR(1)MTR | (0)60 | − (1)Caelyx | sGBM IV HISTO | 60 | 7.4 | 113.6 | 8.4 |
| 8 | M | 60 | R/F-P | AA III | 100 | 1 | (0)SB | (0)60 | (0)TMZ | sGBM IV MRI | 60 | 4.3 | 16.4 | 6.1 |
| 9 | F | 62 | L/P | AA III | 60 | 1 | (0)PR | (0)60 | (0)TMZ | sGBM IV MRI | 50 | No progress | Alive | Alive |
| 10 | M | 44 | R/F | AA III | 90 | 3 | (0)PR | (0)60 | (0)PCV (1, 2)TMZ | sGBM IV MRI | 90 | No progress | Alive | Alive |
| 11 | M | 33 | L-R/F | OA II | 100 | 5 | (0)PR (1, 4)MTR | − (1, 2)60 | − (3)PCV, (4)TMZ | sGBM IV HISTO | 70 | 3 | 169.5 | 4.1 |
↵* Karnofsky Performance Status (KPS) at initial diagnosis and before B/I therapy.
↵† Extended field.
R = right hemisphere; T = temporal; (0) = primary tumor; MTR = macroscopic total resection; (1) = first recurrence; (n) n recurrences until death/evaluation; TMZ = temozolomide; SUT = sunitinib; L = left hemisphere; P = parietal; PR = partial resection; GS = gliosarcoma WHO IV; F = frontal; ODG = oligodendroglioma WHO III–IV; Caelyx = anthracycline; SB = stereotactic biopsy; OA = oligoastrocytoma WHO II.
At initial diagnosis, histology was confirmed in all 11 patients. Before B/I treatment, histology of sGBM was confirmed in 3 of 6 cases (HISTO); 3 cases were diagnosed by MRI (MRI).